Acrux-Organon partnership dropped
Friday, 15 August, 2008
Acrux [ASX: ACR] has announced that projects it had been developing with Dutch pharma Organon have been cancelled after Organon's new owners Schering-Plough pulled the plug.
Acrux and Organon had been collaborating on a transdermal spray that was to add an undisclosed Organon proprietary drug to Acrux's contraceptive spray technology.
Acrux had already delivered on the first stage of the project, developing spray formulations for testing in clinical trials, and had been given $1 million in non-refundable payments on signing the collaboration agreement.
According to Acrux representatives, the decision has had no effect on the company's funding.
Acrux's own contraceptive spray development remains on track, with commercialisation expected to begin next year for several products.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
